SEC INSIDER TRANSACTIONS
AbbVie Inc. (ABBV) Insider Transactions
Explore official ownership filings, with every record linked to its source.
ABBV · AbbVie Inc.
How to read this data ↗
Stale snapshot · Covered: filings 2026-10-15 to 2026-11-13 · 2 filings · fetched 2026-11-13T16:19:07Z
View six-calendar-month insider history →
Recent reported activity
Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.
| Transaction / filed | Reporting owner(s) | Code / security | Quantity | Price as filed | Ownership | Source |
|---|---|---|---|---|---|---|
| 2026-11-12Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: | G GiftCommon Stock, $0.01 par value · Non-derivative | 3,450D | 0 | Direct | Form 4 ↗0001761675-26-000007 |
| 2026-11-09Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F4 | M Exercise / conversionOption (Right to Buy) · Derivative | 24,549D | 0 | Direct | Form 4 ↗0001761675-26-000007 |
| 2026-11-09Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F3 | M Exercise / conversionOption (Right to Buy) · Derivative | 16,070D | 0 | Direct | Form 4 ↗0001761675-26-000007 |
| 2026-11-09Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: F1 | S Sale (market/private)Common Stock, $0.01 par value · Non-derivative | 40,619D | 293.6 | Direct | Form 4 ↗0001761675-26-000007 |
| 2026-11-09Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: | M Exercise / conversionCommon Stock, $0.01 par value · Non-derivative | 24,549A | 93.5 | Direct | Form 4 ↗0001761675-26-000007 |
| 2026-11-09Filed 2026-11-12 | Stewart Jeffrey RyanOfficer · EVP, CHIEF COMMERCIAL OFFICERFiling contextReported filing row; may be amended. Do not sum filings blindly. F1 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2 The reporting person disclaims beneficial ownership of all securities held by his spouse. F3 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4 Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. References: | M Exercise / conversionCommon Stock, $0.01 par value · Non-derivative | 16,070A | 114.36 | Direct | Form 4 ↗0001761675-26-000007 |
Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.